GlobeNewswire by notified

Resultat af auktion over skatkammerbeviser 11. januar 2023

Del

Bud, salg, skæringsrenter og pris fremgår af nedenstående oversigt: 

ISINBud mio. kr. (nominelt)SalgSkæringsrente  (pct.)Pro-rataKurs
98 18858 SKBV 23 / I100
100
1,680 100 %99,7811
98 18932 SKBV 23 / II400
400
2,150 100 %99,1767
I alt500500

Salget bliver afviklet den 13. januar 2023.

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

Ministry of Industry and Mineral Resources Announces Details of Third Edition of Future Minerals Forum11.12.2023 19:36:14 CET | Press release

RIYADH, Saudi Arabia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- At a press conference today, the Ministry of Industry and Mineral Resources (MIM) announced details of the third edition of the Future Minerals Forum (FMF), to be held in Riyadh 9th-11th January at the King Abdulaziz International Conference Center. Speaking at the conference, H.E. the Vice Minister for Mining Affairs, Khalid Al-Mudaifer, looked forward to further achievements delivered by the Ministerial Roundtable and FMF 2024. In previous editions, both platforms have seen participation from ministers and a leading group of international speakers to address issues and turn talk into action. The Vice Minister discussed the unique role of the FMF in hosting the only Ministerial Roundtable of its kind in the industry. He said: "We have succeeded in making this meeting a strategic and influential platform led by governments, providing a voice for many countries and official organizations." Over 70 countries will be represented by g

Mendus presenterar positiva överlevnadsdata från fas 2-studien ADVANCE II som utvärderar vididencel som underhållsbehandling vid AML vid ASH-konferensen11.12.2023 19:30:00 CET | Pressemelding

Pressmeddelande Stockholm, 11 december 2023 Per den 24 november 2023 var återfallsfri medianöverlevnad (mRFS) 30,4 månader Medianen för totalöverlevnad (mOS) hade inte ännu inte uppnåtts, med majoriteten av patienterna (14/20) fortfarande i livet Minskning av mätbar av mätbar restsjukdom (MRD) och induktion av immunsvar korrelerar med fördelar för RFS och OS, vilket bekräftar vididencels verkningsmekanism Virtuellt Key Opinion Leader-event (KOL) med huvudprövare för att diskutera nya ASH-data torsdagen den 14 december 2023 kl. 15.00 CET, anmäl här Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, presenterade idag positiva uppdaterade överlevnadsdata från fas 2-studien ADVANCE II som utvärderar vididencel (DCP-001) vid akut myeloid leukemi (AML), vid konferensen American Society of Hematology’s Annual Meeting (ASH 2023). Data från långtidsuppföljningen visade varaktiga behandlingssvar med överlevnadsnytta som överstiger histori

Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 202311.12.2023 19:30:00 CET | Press release

Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival (mRFS) stood at 30.4 months Median overall survival (mOS) was not reached, with the majority of patients (14/20) still alive Reduction in measurable residual disease (MRD) and induction of immune responses correlate with RFS and OS benefit, confirming vididencel mechanism of action Virtual KOL event with principal investigator to discuss new ASH data on Thursday, December 14, 2023, at 9.00 am ET/3.00 pm CET; register HERE Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced positive updated survival data from the Phase 2 ADVANCE II trial evaluating vididencel (DCP-001) in acute myeloid leukemia (AML) at the American Society of Hematology’s 65th Annual Meeting (ASH 2023). The longer-term follow up data showed durable treatment responses with survival benefit exceeding historical results expected from t

Harbert Management Corporation included in 2023 Pensions & Investments Best Places to Work in Money Management11.12.2023 19:28:04 CET | Press release

BIRMINGHAM, Ala., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Harbert Management Corporation (“HMC”) has been voted one of the Best Places to Work in Money Management for the fifth year in a row. Presented by Pensions & Investments, the global news source of money management and institutional investing, the 12th annual survey and recognition program is dedicated to identifying and recognizing the best employers in the money management industry. HMC prides itself on its history of managing the firm and investment strategies with the utmost integrity. For 30 years HMC has been devoted to investing capital in a responsible manner. We are committed to corporate social responsibility and engaging our employees and stakeholders to pursue opportunities that make positive and long-lasting impacts. Investment excellence, transparency with our clients, and exemplary Fund Administration are the hallmarks of HMC’s commitment to investors. “Pensions & Investments is proud to honor the Best Places to Work in

Holding(s) in Company11.12.2023 18:11:50 CET | Press release

TORONTO, Canada, Dec. 11, 2023 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:Amaroq Minerals Ltd.1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuerX2. Reason for the notification (please mark the appropriate box or boxes with an “X”)An acquisition or disposal of voting rightsXAn acquisition or disposal of financial instrumentsAn event changing the breakdown of voting rightsOther (please specify):3. Details of person subject to the notification obligationNameAkta sjóðir hf., an alternative investment fund manager and a UCITC management company, acting on behalf of funds operated by the company.City and country of registered office (if applicable)Reykjavík, Iceland4. Full name of sha